Publication:
Outcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry

dc.contributor.coauthorHascoet, Sebastien
dc.contributor.coauthorBentham, James R.
dc.contributor.coauthorGiugno, Luca
dc.contributor.coauthorBetrian-Blasco, Pedro
dc.contributor.coauthorKempny, Aleksander
dc.contributor.coauthorHoueijeh, Ali
dc.contributor.coauthorBaho, Haysam
dc.contributor.coauthorSharma, Shiv-Raj
dc.contributor.coauthorJones, Matthew, I
dc.contributor.coauthorBiernacka, Elzbieta Katarzyna
dc.contributor.coauthorCombes, Nicolas
dc.contributor.coauthorGeorgiev, Stanimir
dc.contributor.coauthorBouvaist, Helene
dc.contributor.coauthorMartins, Jose Diogo
dc.contributor.coauthorKantzis, Marinos
dc.contributor.coauthorTurner, Mark
dc.contributor.coauthorSchubert, Stephan
dc.contributor.coauthorJalal, Zakaria
dc.contributor.coauthorButera, Gianfranco
dc.contributor.coauthorMalekzadeh-Milani, Sophie
dc.contributor.coauthorValdeolmillos, Estibaliz
dc.contributor.coauthorKarsenty, Clement
dc.contributor.coauthorOdemis, Ender
dc.contributor.coauthorAldebert, Philippe
dc.contributor.coauthorHaas, Nikolaus A.
dc.contributor.coauthorKhatib, Ihab
dc.contributor.coauthorWahlander, Hakan
dc.contributor.coauthorGaio, Gianpiero
dc.contributor.coauthorMendoza, Alberto
dc.contributor.coauthorArif, Sayqa
dc.contributor.coauthorCastaldi, Biagio
dc.contributor.coauthorDohlen, Gaute
dc.contributor.coauthorCarere, Ronald G.
dc.contributor.coauthorDel Cerro-Marin, Maria Jesus
dc.contributor.coauthorKitzmueller, Erwin
dc.contributor.coauthorHermuzi, Antony
dc.contributor.coauthorCarminati, Mario
dc.contributor.coauthorGuerin, Patrice
dc.contributor.coauthorTengler, Anja
dc.contributor.coauthorFraisse, Alain
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorÖdemiş, Ender
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:33:11Z
dc.date.issued2023
dc.description.abstractBackground and Aims Transcatheter pulmonary valve implantation (TPVI) is indicated to treat right-ventricular outflow tract (RVOT) dysfunction related to congenital heart disease (CHD). Outcomes of TPVI with the SAPIEN 3 valve that are insufficiently documented were investigated in the EUROPULMS3 registry of SAPIEN 3-TPVI.Methods Patient-related, procedural, and follow-up outcome data were retrospectively assessed in this observational cohort from 35 centres in 15 countries.Results Data for 840 consecutive patients treated in 2014-2021 at a median age of 29.2 (19.0-41.6) years were obtained. The most common diagnosis was conotruncal defect (70.5%), with a native or patched RVOT in 50.7% of all patients. Valve sizes were 20, 23, 26, and 29 mm in 0.4%, 25.5%, 32.1%, and 42.0% of patients, respectively. Valve implantation was successful in 98.5% [95% confidence interval (CI), 97.4%-99.2%] of patients. Median follow-up was 20.3 (7.1-38.4) months. Eight patients experienced infective endocarditis; 11 required pulmonary valve replacement, with a lower incidence for larger valves (P = .009), and four experienced pulmonary valve thrombosis, including one who died and three who recovered with anticoagulation. Cumulative incidences (95%CI) 1, 3, and 6 years after TPVI were as follows: infective endocarditis, 0.5% (0.0%-1.0%), 0.9% (0.2%-1.6%), and 3.8% (0.0%-8.4%); pulmonary valve replacement, 0.4% (0.0%-0.8%), 1.3% (0.2%-2.4%), and 8.0% (1.2%-14.8%); and pulmonary valve thrombosis, 0.4% (0.0%-0.9%), 0.7% (0.0%-1.3%), and 0.7% (0.0%-1.3%), respectively.Conclusions Outcomes of SAPIEN 3 TPVI were favourable in patients with CHD, half of whom had native or patched RVOTs. Structured Graphical Abstract Cumulative incidence of valvular replacement after transcatheter pulmonary SAPIEN 3 valve implantation in patients with congenital heart diseases 10.1093/eurheartj/ehad663_audio1 Audio Abstract ehad663_audio1 6339523571112
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.issue3
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.sponsorshipThis work was supported by a research grant to the Department of Research and Innovation, Marie Lannelongue Hospital, Groupe Hospitalier Paris-Saint Joseph, France.
dc.description.volume45
dc.identifier.doi10.1093/eurheartj/ehad663
dc.identifier.eissn1522-9645
dc.identifier.issn0195-668X
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85181891896
dc.identifier.urihttps://doi.org/10.1093/eurheartj/ehad663
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26563
dc.identifier.wos1091004400001
dc.keywordsPulmonary valve
dc.keywordsCongenital heart disease
dc.keywordsPercutaneous pulmonary valve implantation
dc.keywordsTranscatheter pulmonary valve replacement
dc.keywordsSAPIEN 3
dc.keywordsSAPIEN 3 Ultra
dc.language.isoeng
dc.publisherOxford Univ Press
dc.relation.grantnoDepartment of Research and Innovation, Marie Lannelongue Hospital, Groupe Hospitalier Paris-Saint Joseph, France
dc.relation.ispartofEuropean Heart Journal
dc.subjectMedicine
dc.titleOutcomes of transcatheter pulmonary SAPIEN 3 valve implantation: an international registry
dc.typeJournal Article
dspace.entity.typePublication
local.contributor.kuauthorÖdemiş, Ender
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files